ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / WAT
A (72) MTD (78) RVTY (65) AVTR (56) ⌘ Pro Terminal →

Waters Corporation (WAT) — RQD Stock Rating Cockpit

$462.72 -3.61% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $460.82

Waters Corporation (WAT) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (59% profit margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate) →
ROARABLE B • BUY Cap $45.46B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WAT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Waters Corporation (NYSE: WAT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $462.72 (-3.61% 1D, market cap $45.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WAT ranks #56 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WAT compare to A and MTD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), WAT carries a Roarable B (72/100 RQD), trailing P/E of 73.4x, gross margin of 59.3%, and ROIC of 16.8%. By comparison, A (Agilent Technologies Inc.) holds a B grade (72/100 RQD, P/E 39.2x, ROIC 15.3%, cap $49.30B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WAT?
▼

Per WAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001000697), Waters Corporation generated $3.17B in revenue (+7.0% YoY), $642.6M in net income, and $510.1M in free cash flow against $5.08B in total assets and $947.0M in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $460.82 (-0.41%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 16.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B
Cash (15)Whales (18)SEC (16)Macro (14)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$580 Bull$492 Base$379 Bear
📬 FREE WAT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WAT)Realized 20D OHLCV Swing Band: ±6.5%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY WAT SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (25% of score)

20D Institutional Volume Accumulation (±6.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 15.49 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$436.61+4.8% Next Q
Q2 (-2Q)
67
Grade B-$457.47+4.2% Next Q
Q3 (-1Q)
69
Grade B-$476.88-3% Next Q
Current
72
Grade B$462.72+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the WAT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, WAT faces multiple-compression risk if 73.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 73x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($433.92) or 200D SMA ($370.80) invalidates the momentum regime and cuts Target Base ($491.87) toward Bear Floor ($379.43).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WAT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “WAT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
55.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
15.49>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE90% OF RANGE
L: $283$462.72H: $482
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (59% profit margin and healthy balance-sheet cushion).

Factor Grade: BRQD 15 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C+RQD 27 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on WAT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (75)

16.8% ROIC with 59.3% gross margin and 1.08% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 15.49 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (68)

27/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like WAT
  • ✓Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Priced at 73x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (WAT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
WAT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +53.28%▲ ASCENDING CHANNEL
2026-11-03O $480.1H $480.1L $462.7C $462.7VOL 1.34M
RES: $488.8SUP: $444.7SMA50: $433.9SMA200: $370.8
$495.1$441.9$388.8$335.6$282.4RES $488.8SUP $444.7$462.72026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WAT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WAT Butterfly Map → + Track WAT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
47.3%/yr Implied 5Y Growth

vs. +7.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WAT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WAT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for WAT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WAT)

Health Care Rank #56 of 1016 ⚔️ A vs WAT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WAT vs. A, MTD, RVTY, AVTR)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Waters Corporation (WAT) ranks #56 by composite RQD confidence (72/100, grade B) and #41 by equity capitalization ($45.46B). Within this direct 5-issuer industry benchmark cohort, A leads on earnings valuation at 39.2x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with WAT at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
WAT ACTIVE
Waters Corporation
B 72/100 73.4x 59.3% 16.8% -3.61% $45.46B Benchmark Subject
A
Agilent Technologies Inc.
B 72/100 39.2x 52.4% 15.3% -3.47% $49.30B /a-vs-wat →
MTD
Mettler-Toledo International Inc.
B+ 78/100 39.6x 59.4% 30.4% -2.55% $33.56B /mtd-vs-wat →
RVTY
Revvity Inc.
C 65/100 76.7x — 3.1% -5.30% $17.52B /rvty-vs-wat →
AVTR
Avantor Inc.
D+ 56/100 — 32.7% -2.1% -3.78% $10.88B /avtr-vs-wat →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001000697

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Waters Corporation (WAT) reported GAAP revenue of $3.17B (+7.0% vs. FY2024 revenue of $2.96B , and +7.1% cumulative change since FY2023) , GAAP net income of $642.6M, operating cash flow of $652.6M, and free cash flow of $510.1M (-18.9% YoY). On the balance sheet, WAT closed FY2025 with $5.08B in total assets against $947.0M in total debt (Altman Z-Score: 15.49, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.17B $642.6M $652.6M $510.1M $5.08B $947.0M
FY2024 (FY) 2024-12-31 $2.96B $637.8M $762.1M $629.0M $4.55B $1.63B
FY2023 (FY) 2023-12-31 $2.96B $642.2M $602.8M $469.8M $25.94B $6.07B

3. WAT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WAT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Waters Corporation (NYSE: WAT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $462.72 (-3.61% 1D, market cap $45.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, WAT ranks #56 in composite RQD confidence.

How does WAT compare to A and MTD in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), WAT carries a Roarable B (72/100 RQD), trailing P/E of 73.4x, gross margin of 59.3%, and ROIC of 16.8%. By comparison, A (Agilent Technologies Inc.) holds a B grade (72/100 RQD, P/E 39.2x, ROIC 15.3%, cap $49.30B) and MTD (Mettler-Toledo International Inc.) posts a B+ grade (78/100 RQD, P/E 39.6x, ROIC 30.4%, cap $33.56B). Among the 5-stock peer group, A leads on earnings multiple (39.2x) while MTD leads on capital efficiency (30.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for WAT?

Per WAT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001000697), Waters Corporation generated $3.17B in revenue (+7.0% YoY), $642.6M in net income, and $510.1M in free cash flow against $5.08B in total assets and $947.0M in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is WAT trading relative to its 50-day, 200-day, and 52-week technical levels?

WAT last traded at $462.72 (-3.61% on volume of 1,342,328 shares), positioning the stock +6.64% above its 50-day simple moving average ($433.92) and +24.79% above its 200-day simple moving average ($370.80). Across its 52-week range of $282.77 to $482.28, WAT sits at the 90.2% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.5% ($432.64 to $492.80).

WAT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell WAT stock right now?

Waters Corporation (WAT) currently earns a Roarable Rating of B (Buy — BUY) with 72/100 RQD Confidence. High-quality cash engine (59% profit margin, 17% return on capital) with steady institutional support.

What is WAT's 12-month price target and RQD AI Jury consensus?

WAT's 12-month base price target is $491.87 (range $379.43 to $580.41), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: WAT RQD Cockpit WAT 12M Forecast WAT Earnings & Move WAT Dividends & DRIP WAT Insiders & 13F WAT Whale Options WAT Profit Sankey WAT News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

WAT — Waters Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:11:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, WAT carries an RQD score of 73 out of 100, a letter grade of B, and a verdict label of "Roarable Buy — Good Risk/Reward." The score is built from five pillars. The Fundamental Cash Engine pillar scores 15 of 20, supported by ROIC of 16.8% and an FCF yield of 1.08%; for a prospective investor, this indicates the business generates solid returns on capital, but the cash return relative to the current price is thin. The Whale 13F Flow pillar scores 19 of 20, reflecting institutional accumulation and options positioning, the strongest pillar and a potential upside driver if that positioning persists. The Insider Conviction pillar scores 9 of 20, based on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar and a point of caution. The Macro Regime Fit pillar scores 14 of 20, with a beta of 1.02 and sector sensitivity, suggesting the stock tracks broad market movement closely. The Forensic Balance Sheet pillar scores 16 of 20, supported by an Altman Z-Score of 15.49, a Piotroski F-Score of 9 of 9, and Debt/Equity of 0.37. Valuation is the central tradeoff: a P/E (TTM) of 73.4, a forward P/E of 68.3, and an EV/EBITDA of 51.5 indicate that the price already embeds substantial expectations, so the rating's favorable read depends on those expectations being met.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$480.07$47.17B73.468.351.56.540%1.02$282.77 - $482.2816.8%

Business

Waters Corporation is a NYSE-listed issuer classified under the Health Care sector and the Biotechnology: Laboratory Analytical Instruments industry. Per the profile, the company operates in laboratory analytical instruments. Per the SEC financials, the company reports revenue of $3165.3M for FY 2025 and gross margin of 59.3%. Customer segments and specific product lines are not available in source data.

Recent Catalysts & News Wire Analysis

Six news items are provided, all tagged to WAT. Two carry a GREEN "CATALYST" light, and four carry YELLOW "MARKET WIRE" lights. The GREEN item is a Simply Wall St report headlined "Waters (WAT) Stock Looks Fully Valued Despite Fresh Growth News," which the source tags as a catalyst. Other items include a Yahoo Finance preview of Q3 earnings, a TradingView piece on retaining the stock, a Simply Wall St analyst forecast piece, and general quote pages. Risk watch items include the valuation concern raised in the GREEN-tagged headline itself. Per the Butterfly Supply-Chain Graph, there are no proprietary signals and no butterfly links; the supply_chain field reads NONE.

Open Questions

  • What are the consensus analyst rating and price targets, given that no analyst data is supplied?
  • Which specific insiders or institutions drove the 19 of 20 Whale 13F Flow score, and what is their trade timing?
  • What drove the FY 2024 to FY 2025 revenue increase, and what segments contributed?
  • What is the EPS for each reported fiscal year, since the EPS field reads N/A in the financials?
  • What accounts for the FY 2023 cash figure being unavailable, and what is the composition of the FY 2023 debt of $6070.3M?

WAT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Waters Corporation (WAT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WAT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WAT Bull vs. Bear Conversation Board — What's Your Call at $462.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WAT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on WAT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $566.48 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is WAT (B • RQD 73/100) a Buy at $480.07?

Welcome to the WAT (Waters Corporation) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Laboratory Analytical Instruments. Bulls point to capital efficiency (16.8% ROIC), while bears focus on valuation multiple compression (73.4x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $403.26 (-16.0%)
Spot @ $480.07

Pump the brakes on WAT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on WAT, but look at what you are paying: 73.4x trailing P/E with 59.3% gross margins. Unless Waters Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $571.28 (+19.0%)
Spot @ $480.07

WAT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on WAT, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $480.07 (52-wk range $282.77 - $482.28), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%